# EDGAR Filing Document

**Accession Number:** 0001326205
**File Stem:** 0001185185-25-001023
**Filing Date:** 2025-8
**Character Count:** 5590
**Document Hash:** 2b9e68fc163577db89851093cbc7697d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001185185-25-001023.hdr.sgml**: 20250819

**ACCESSION NUMBER**: 0001185185-25-001023

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 5

**FILED AS OF DATE**: 20250819

**DATE AS OF CHANGE**: 20250818

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IGC Pharma, Inc.
- **CENTRAL INDEX KEY:** 0001326205
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 202760393
- **STATE OF INCORPORATION:** MD
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-32830
- **FILM NUMBER:** 251229254

**BUSINESS ADDRESS:**
- **STREET 1:** 10224 FALLS ROAD
- **CITY:** POTOMAC
- **STATE:** MD
- **ZIP:** 20854
- **BUSINESS PHONE:** 301-983-0998

**MAIL ADDRESS:**
- **STREET 1:** 10224 FALLS ROAD
- **CITY:** POTOMAC
- **STATE:** MD
- **ZIP:** 20854

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** India Globalization Capital, Inc.
- **DATE OF NAME CHANGE:** 20050505

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14A**

**Proxy Statement Pursuant to Section 14(a) of the**

**Securities Exchange Act of 1934**

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material Pursuant to §240.14a-12

![igcpharma20240709_defa14aimg001.jpg](image_001.jpg)

**<u>IGC Pharma, Inc.</u>**

(Exact name of registrant as specified in its charter)

<u> </u>

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

☒ No fee required.

☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

☐ Fee paid previously with preliminary materials.

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

---

| |
|:---|
| **Your Vote Counts!**<br> **IGC PHARMA, INC.<br> 2025 Annual Meeting<br> Vote by October 09, 2025<br> 11:59 PM ET** |
| ![](image_002.jpg) |

---

**You invested in IGC PHARMA, INC. and it's time to vote!**

You have the right to vote on proposals being presented at the Annual Meeting. **This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on October 10, 2025.**

**Get informed before you vote**

View the Notice & Proxy Statement, Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to September 28, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

---

| | |
|:---|:---|
| ![](image_003.jpg) | **Vote in Person at the Meeting\***<br> October 10, 2025<br> 11:00 AM EST |
| 10224 Falls Road<br> Potomac, Maryland, 20854 | 10224 Falls Road<br> Potomac, Maryland, 20854 |

---

------

\* If you choose to vote these shares in person at the meeting, you must request a "legal proxy." To do so, please follow the instructions at www.ProxyVote.com or request a paper copy of the materials, which will contain the appropriate instructions. Please check the meeting materials for any special requirements for meeting attendance.

---

| | |
|:---|:---|
| **THIS IS NOT A VOTABLE BALLOT**<br>This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**IGC PHARMA, INC.**<br> 2025 Annual Meeting<br> Vote by October 09, 2025<br> 11:59 PM ET |

---

---

| | | |
|:---|:---|:---|
| **Voting Items** | **Voting Items** | **Board<br> Recommends** |
| 1. | Election of Directors | **For** |
|  | **Nominees:** |  |
| 1A | MR. RAM MUKUNDA |  |
| 1B | MR. JAMES MORAN | **For** |
| 2 | To ratify the appointment of Manohar Chowdhry & Associates, as the Company's independent registered public accounting firm for the 2026 fiscal year | **For** |
| 3 | To approve the grant of 5,000,000 shares of common stock, governed by the Company's 2018 Omnibus Incentive Plan, to be granted from time to time to the Company's current and new employees, advisors, directors, and consultants by the Board of Directors, pursuant to certain metrics including performance, vesting, and incentive as set by the Board of Directors and or the CEO | **For** |
| 4 | To effect an amendment to our Amended and Restated Articles of Incorporation to increase the authorized number of shares of our common stock from 150,000,000 shares to 600,000,000 shares of common stock | **For** |
| 5 | To act upon such other matters as may properly come before the Annual Meeting, including any proposal to adjourn or postpone of the Annual Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies (the Adjournment Proposal) Such other business as may properly come before the meeting or any adjournment thereof | **For** |

---